Von Willebrand disease, type 2A
ICD-10 D68.020 is a billable code used to indicate a diagnosis of von willebrand disease, type 2a.
Von Willebrand disease (VWD) type 2A is a hereditary bleeding disorder characterized by a deficiency or dysfunction of von Willebrand factor (VWF), a protein crucial for platelet adhesion and aggregation. This type of VWD is caused by qualitative defects in VWF, leading to impaired platelet function and increased bleeding tendency. Patients may present with symptoms such as easy bruising, prolonged bleeding from cuts, heavy menstrual periods, and spontaneous nosebleeds. The diagnosis is typically confirmed through laboratory tests that assess VWF levels and function, including ristocetin cofactor activity and VWF antigen levels. Management often involves desmopressin administration to increase VWF levels, along with factor replacement therapies in severe cases. Understanding the nuances of VWD type 2A is essential for effective treatment and management of bleeding episodes, as well as for genetic counseling for affected families.
Comprehensive documentation of patient history, laboratory results, and treatment plans.
Patients presenting with unexplained bleeding, family history of bleeding disorders, or requiring surgical procedures.
Ensure accurate coding based on specific type of VWD and associated symptoms.
Detailed family history and genetic testing results.
Genetic counseling for families with a history of VWD or other bleeding disorders.
Documentation should include genetic testing outcomes and implications for family members.
Used for laboratory tests to assess VWF levels.
Document the reason for blood draw and any relevant patient history.
Ensure that the specialty performing the test is noted.
Common symptoms include easy bruising, prolonged bleeding from cuts, heavy menstrual bleeding, and frequent nosebleeds.
Diagnosis is made through laboratory tests that measure von Willebrand factor levels and function, including VWF antigen and ristocetin cofactor activity.
Treatment options include desmopressin to stimulate VWF release and factor replacement therapies for more severe cases.
